Your session is about to expire
← Back to Search
Behavioural Intervention
Pilot TMS for Methamphetamine Use Disorder
N/A
Waitlist Available
Led By Ryan Carnahan, PharmD, MS
Research Sponsored by University of Iowa
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a new magnetic pulse treatment for people struggling with methamphetamine addiction. The treatment targets specific brain areas to help reduce cravings and improve self-control. It aims to see if this method can be more effective than typical treatments.
Eligible Conditions
- Stimulant Addiction
- Methamphetamine Addiction
- Substance Addiction
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 1 week, 2 weeks, 3 weeks, 4 weeks, 8 weeks, 12 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Retention in psychosocial treatment
Retention in the study
Secondary study objectives
Assessment of Recovery Capital
Brief Addiction Monitor Protective Factors Subscale
Brief Addiction Monitor Risk Factors Subscale
+18 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: MPFC firstExperimental Treatment1 Intervention
Participants in this arm will undergo all study procedures including consent; pre-, during, and post-psychological assessments; pre- and post- MRI and fMRI; 16 treatments of dual target TMS over a 4-week period; and substance use-related assessments to include substance use, withdrawal symptoms, and cravings to use. This arm will receive the medial prefrontal cortex stimulation first.
Group II: DPFC firstExperimental Treatment1 Intervention
Participants in this arm will undergo all study procedures including consent; pre-, during, and post-psychological assessments; pre- and post- MRI and fMRI; 16 treatments of dual target TMS over a 4-week period; and substance use-related assessments to include substance use, withdrawal symptoms, and cravings to use. This arm will receive the dorsolateral prefrontal cortex stimulation first.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Magnetic Stimulation
2017
Completed Phase 4
~730
Find a Location
Who is running the clinical trial?
University of New MexicoOTHER
388 Previous Clinical Trials
3,526,584 Total Patients Enrolled
University of UtahOTHER
1,147 Previous Clinical Trials
1,699,101 Total Patients Enrolled
University of IowaLead Sponsor
471 Previous Clinical Trials
894,642 Total Patients Enrolled
Ryan M. CarnahanLead Sponsor
1 Previous Clinical Trials
44,524 Total Patients Enrolled
Ryan Carnahan, PharmD, MSPrincipal InvestigatorUniversity of Iowa
1 Previous Clinical Trials
44,524 Total Patients Enrolled
Alison C Lynch, MD, MSPrincipal InvestigatorUniversity of Iowa